TWI362270B - - Google Patents

Download PDF

Info

Publication number
TWI362270B
TWI362270B TW095140210A TW95140210A TWI362270B TW I362270 B TWI362270 B TW I362270B TW 095140210 A TW095140210 A TW 095140210A TW 95140210 A TW95140210 A TW 95140210A TW I362270 B TWI362270 B TW I362270B
Authority
TW
Taiwan
Prior art keywords
group
peptide
lipid
reactive functional
spacer
Prior art date
Application number
TW095140210A
Other languages
English (en)
Chinese (zh)
Other versions
TW200819137A (en
Inventor
Te We Lee
Shu Pei Chiu
Chiu Yu Yu
Tsui Jung Chang
Chih Hsien Chang
Original Assignee
Iner Aec Executive Yuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iner Aec Executive Yuan filed Critical Iner Aec Executive Yuan
Priority to TW095140210A priority Critical patent/TW200819137A/zh
Priority to US11/608,836 priority patent/US20080102110A1/en
Priority to JP2006350627A priority patent/JP2008115147A/ja
Priority to US12/029,324 priority patent/US20080139703A1/en
Publication of TW200819137A publication Critical patent/TW200819137A/zh
Application granted granted Critical
Publication of TWI362270B publication Critical patent/TWI362270B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW095140210A 2006-10-31 2006-10-31 Method for preparation of lipid-spacer radical- reactions of functional group-peptide TW200819137A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TW095140210A TW200819137A (en) 2006-10-31 2006-10-31 Method for preparation of lipid-spacer radical- reactions of functional group-peptide
US11/608,836 US20080102110A1 (en) 2006-10-31 2006-12-10 Method for Preparing Lipid-Spacer-Reactive Functional Group-Peptide
JP2006350627A JP2008115147A (ja) 2006-10-31 2006-12-26 脂質−スペーサ−官能基−ペプチドを製造する方法
US12/029,324 US20080139703A1 (en) 2006-10-31 2008-02-11 Method for Preparing Lipid-Spacer-Reactive Functional Group-Peptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW095140210A TW200819137A (en) 2006-10-31 2006-10-31 Method for preparation of lipid-spacer radical- reactions of functional group-peptide

Publications (2)

Publication Number Publication Date
TW200819137A TW200819137A (en) 2008-05-01
TWI362270B true TWI362270B (enExample) 2012-04-21

Family

ID=39330477

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095140210A TW200819137A (en) 2006-10-31 2006-10-31 Method for preparation of lipid-spacer radical- reactions of functional group-peptide

Country Status (3)

Country Link
US (2) US20080102110A1 (enExample)
JP (1) JP2008115147A (enExample)
TW (1) TW200819137A (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120015026A1 (en) * 2009-03-25 2012-01-19 Giancarlo Francese Pharmaceutical composition containing a drug and sirna
TWI397428B (zh) * 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
US10611796B2 (en) 2016-03-16 2020-04-07 Council Of Scientific & Industrial Research Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE2512T1 (de) * 1979-11-27 1983-03-15 Sandoz Ag Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.
DE69124274T2 (de) * 1990-02-27 1997-08-14 Agency Ind Science Techn Oligopeptide, sie enthaltende pharmazeutische und Futterzusammensetzung und Benützung von Oligopeptiden
WO1997031624A1 (en) * 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
AU2620000A (en) * 1999-01-21 2000-08-07 Georgetown University Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
JP2004510751A (ja) * 2000-10-05 2004-04-08 アレス　トレーディング　ソシエテ　アノニム 位置選択的液相ペグ化
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same

Also Published As

Publication number Publication date
US20080102110A1 (en) 2008-05-01
JP2008115147A (ja) 2008-05-22
TW200819137A (en) 2008-05-01
US20080139703A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
US20150218252A1 (en) Self-assembling peptides, peptide nanostructures and uses thereof
CA2452923C (en) Peptide-based compounds for targeting integrin receptors
US7452679B2 (en) Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof
CA2405469C (en) Integrin binding peptide derivatives
CN104011065B (zh) 肽纳米粒子及其用途
JP2002535247A (ja) 輸送系複合体
CN101538313A (zh) 肽基化合物
WO2004003561A1 (en) Peptide rod amphiphiles and self-assembly of same
US20070140972A1 (en) Targeting compositions and preparation therof
Helbok et al. Targeting properties of peptide-modified radiolabeled liposomal nanoparticles
TWI362270B (enExample)
JP4566406B2 (ja) Ｇｉｔ輸送受容体を標的とするレトロ反転ペプチド及び関連する方法
WO1994011015A1 (en) Lipophilic peptide-based carriers for targeted drug delivery using rational drug-binding design
Ziora et al. Lipopeptides for the fragment-based pharmaceutics design
JP2018534317A (ja) 結腸がんの処置および検出のための組成物および方法
TW202540145A (zh) 胜肽及包含該胜肽之偶聯物
Cho Self-Assembling Lipopeptide Nanocarriers for Targeted Cellular Uptake
NZ622045B2 (en) Peptide nanoparticles and uses thereof
HK1193115B (en) Peptide nanoparticles and uses thereof
HK1193115A (en) Peptide nanoparticles and uses thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees